Todos Medical Ltd. (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive the in vitro diagnostics company has received a $3.4 million strategic investment from tech-focused venture capital firm Yozma Group Korea.
Commissiong says Todos intends to use the proceeds from the Investment primarily to retire outstanding convertible notes, complete the acquisition of Provista Diagnostics for its Videssa breast cancer test and its COVID-19 PCR testing capabilities, and general working capital.
Price: 0.0459 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Todos Medical Ltd. named herein, including the promotion by the Company of Todos Medical Ltd. in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE
Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong tells it has signed an agreement with Aditx Therapeutics Inc (NASDAQ:ADTX), through which it has secured the rights to distribute Aditx’s immune-related AditxtScore COVID-19 scoring system, with planned availability in January...
Finance
Industry & services
Prev article
